Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Equity Average (2016 - 2025)

Historic Equity Average for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to $535.9 million.

  • Arrowhead Pharmaceuticals' Equity Average rose 33370.02% to $535.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $535.9 million, marking a year-over-year increase of 33370.02%. This contributed to the annual value of $347.2 million for FY2025, which is 4522.01% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Equity Average of $535.9 million as of Q4 2025, which was up 33370.02% from $512.9 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Equity Average ranged from a high of $603.3 million in Q2 2025 and a low of $123.6 million during Q4 2024
  • For the 5-year period, Arrowhead Pharmaceuticals' Equity Average averaged around $400.8 million, with its median value being $420.0 million (2021).
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Equity Average plummeted by 4637.65% in 2024, and later skyrocketed by 33370.02% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Equity Average stood at $390.7 million in 2021, then rose by 4.27% to $407.4 million in 2022, then crashed by 43.43% to $230.4 million in 2023, then crashed by 46.38% to $123.6 million in 2024, then surged by 333.7% to $535.9 million in 2025.
  • Its last three reported values are $535.9 million in Q4 2025, $512.9 million for Q3 2025, and $603.3 million during Q2 2025.